Actuate Therapeutics Stock Forecast

ACTU's stock price has decreased by -72.85% in the past year and price targets may not have had time to catch up.

Stock Price Forecast

The 2 analysts that cover Actuate Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $17.5, which forecasts a 741.35% increase in the stock price over the next year. The lowest target is $15 and the highest is $20.

Price Target: $17.5 (+741.35%)

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$15	$17.5	$20	$20
Change	+621.15%	+741.35%	+861.54%	+861.54%

Analyst Ratings

The average analyst rating for Actuate Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Nov '25	Dec '25	Jan '26	Feb '26	Mar '26	Apr '26
Strong Buy	2	2	2	2	2	2
Buy	0	0	0	0	0	0
Hold	0	0	0	0	0	0
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	2	2	2	2	2	2

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Swayampakula Ramakanth HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy Maintains $20 → $15	Strong Buy	Maintains	$20 → $15	+621.15%	Apr 13, 2026
Swayampakula Ramakanth HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy Reiterates $20	Strong Buy	Reiterates	$20	+861.54%	Nov 19, 2025
Swayampakula Ramakanth HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy Reiterates $20	Strong Buy	Reiterates	$20	+861.54%	Sep 23, 2025
Mayank Mamtani B. Riley Securities	B. Riley Securities	Strong Buy Initiates $20	Strong Buy	Initiates	$20	+861.54%	Aug 26, 2025
Swayampakula Ramakanth HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy Reiterates $20	Strong Buy	Reiterates	$20	+861.54%	Aug 18, 2025

More Analyst Ratings

Financial Forecast

Revenue This Year

n/a

Revenue Next Year

4.24M

EPS This Year

-1.01

from -1.06

EPS Next Year

-1.43

from -1.01

Fiscal Year	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027	FY 2028
Period Ending	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026	Dec 31, 2027	Dec 31, 2028
Revenue	-	-	-	-	-	4.24M	24.10M
Revenue Growth	-	-	-	-	-	-	468.42%
EPS	-16.65	-17.24	-3.26	-1.06	-1.01	-1.43	-1.38
EPS Growth	-	-	-	-	-	-	-
Forward PE	-	-	-	-	-	-	-
No. Analysts	-	-	-	-	6	6	6

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2026	2027
High	n/a	13.1M
Avg	n/a	4.2M
Low	n/a	n/a

Revenue Growth

Revenue Growth	2026	2027
High	-	-
Avg	-	-
Low	-	-

EPS Forecast

EPS	2026	2027
High	-0.75	-1.10
Avg	-1.01	-1.43
Low	-1.24	-2.11

EPS Growth

EPS Growth	2026	2027
High	-	-
Avg	-	-
Low	-	-

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.